MercoPress. South Atlantic News Agency

Nobel in chemistry for advancing inner workings of G-protein-coupled receptors

Lefkowitz and Kobilka pionners in helping develop better drugs

Two US scientists won the 2012 Nobel Prize for chemistry for research into how cells respond to external stimuli that is helping to develop better drugs to fight diseases such as diabetes, cancer and depression.

The Royal Swedish Academy of Sciences said the 8 million crown (1.2 million dollars) prize went to Robert Lefkowitz, 69, and Brian Kobilka, 57, for discovering the inner workings of G-protein-coupled receptors, which allow cells to respond to chemical messages such as adrenaline rushes.

“Around half of all medications act through these receptors, among them beta blockers, antihistamines and various kinds of psychiatric medications,” the committee said.

Working out better ways to target the receptors, known as GPCRs, is an area of keen focus for pharmaceutical and biotechnology companies.

Lefkowitz told a news conference by telephone he was asleep when the phone call came from Sweden. “I did not hear it - I must share with you that I wear earplugs to sleep. So my wife gave me an elbow. So there it was, a total shock and surprise,” he said.

Sven Lidin, Professor of Inorganic Chemistry at Lund University and chairman of the committee, told a news conference the discovery had been key in medical research.

”Knowing what they (the receptors) look like and how they function will provide us with the tools to make better drugs with fewer side effects,“ he added.

GPCRs are linked to a wide range of diseases, since they play a central role in many biological functions in the body, but developing new drugs to target them accurately has been difficult because of a lack of fundamental understanding as to how they function. Experts say the work of the Nobel Prize winners has opened the door to making better medicines.

Drugs targeting GPCRs have potential in treating illnesses involving the central nervous system, heart conditions, inflammation and metabolic disorders.

Mark Downs, chief executive of Britain's Society of Biology, said the researchers had covered important ground in more than one discipline.

”This ground-breaking work spanning genetics and biochemistry has laid the basis for much of our understanding of modern pharmacology as well as how cells in different parts of living organisms can react differently to external stimulation,“ he said in a statement.

Johan Aqvist, Professor of Chemistry at Sweden's Uppsala University, said Lefkowitz was ”the father of this entire field“.

”Out of the roughly 1,400 drugs that exist in the world, about 1,000 of them are little pills that you consume, and the majority of these are based in these receptors” he said.